22,935 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Bayesian Capital Management LP

Bayesian Capital Management LP purchased a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX) during the 1st quarter, HoldingsChannel.com reports. The fund purchased 22,935 shares of the company’s stock, valued at approximately $177,000.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in Travere Therapeutics by 10.9% in the third quarter. Vanguard Group Inc. now owns 4,667,458 shares of the company’s stock valued at $41,727,000 after buying an additional 460,176 shares during the last quarter. Parkman Healthcare Partners LLC increased its holdings in Travere Therapeutics by 76.4% in the fourth quarter. Parkman Healthcare Partners LLC now owns 1,018,812 shares of the company’s stock valued at $9,159,000 after buying an additional 441,318 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Travere Therapeutics by 79.2% in the first quarter. Russell Investments Group Ltd. now owns 184,623 shares of the company’s stock valued at $1,423,000 after buying an additional 81,611 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Travere Therapeutics in the first quarter valued at about $452,000. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Travere Therapeutics in the fourth quarter valued at about $5,711,000.

Travere Therapeutics Stock Performance

Shares of NASDAQ TVTX opened at $9.24 on Friday. The company has a current ratio of 2.78, a quick ratio of 2.75 and a debt-to-equity ratio of 5.10. The stock has a 50 day simple moving average of $8.30 and a 200-day simple moving average of $7.77. The company has a market cap of $703.44 million, a PE ratio of -4.40 and a beta of 0.77. Travere Therapeutics, Inc. has a 12-month low of $5.12 and a 12-month high of $16.79.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Monday, May 6th. The company reported ($1.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.78). The business had revenue of $41.40 million for the quarter, compared to analyst estimates of $43.46 million. Travere Therapeutics had a negative return on equity of 238.06% and a negative net margin of 87.94%. The business’s quarterly revenue was up 34.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.27) earnings per share. On average, equities research analysts forecast that Travere Therapeutics, Inc. will post -3.92 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on TVTX shares. HC Wainwright reissued a “buy” rating and issued a $19.00 price objective on shares of Travere Therapeutics in a report on Tuesday, May 7th. Wedbush reissued an “outperform” rating and issued a $13.00 price objective on shares of Travere Therapeutics in a report on Wednesday, April 17th. Finally, Canaccord Genuity Group boosted their price objective on Travere Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Travere Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $14.64.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.